Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …

Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …

This report presents 2012 US final mortality data on deaths and death rates by demographic
and medical characteristics. These data provide information on mortality patterns among …

The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …

Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor involved in
homeostatic regulation of normal cells and carcinogenesis of epithelial malignancies. With …

The first cancer-targeted microRNA (miRNA) drug—MRX34, a liposome-based miR-34
mimic—entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in …

Breast cancer affects approximately 1 in 8 women, and it is estimated that over 246,660
women in the USA will be diagnosed with breast cancer in 2016. Breast cancer mortality has …

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …